NYSE$CVSA
Covista Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Adtalem's results for Q2 2022, which ended December 31, 2021, were announced, revealing a revenue increase driven by the Walden acquisition, alongside a pending sale of the Financial Services segment and continued COVID-19 headwinds.
Adtalem Global Education reported a 58.4% increase in revenue to $371.2 million compared to the prior year, driven by the acquisition of Walden. Diluted earnings per share were $0.36, while operating income was $24.7 million. The company announced the pending sale of its Financial Services segment and revised its full-year guidance.
- Revenue increased 58.4% year-over-year to $371.2 million due to the Walden acquisition.
- Diluted earnings per share were reported at $0.36, compared to $0.44 in the prior year.
- Operating income was $24.7 million, down from $29.1 million in the prior year.
- Adtalem revised its full-year guidance due to the pending sale of the Financial Services segment and continued COVID-19 headwinds.
Headline financials
Revenue & EPS history
Adtalem · Revenue · Quarterly
$371M
Revenue by segment
Adtalem · $371M total across 3 segments · Q2 2022
- Walden$141M—37.9%
- Chamberlain$139M—37.5%
- Medical and Veterinary$91.5M—24.6%
Forward guidance
Adtalem revised its full fiscal year 2022 guidance for adjusted revenue, excluding special items, to be within the range of $1,350 million and $1,390 million, and adjusted diluted earnings per share of $2.90 to $3.10 from continuing operations, excluding special items.
Tailwinds
- Focus as a pure play, leading provider of talent to the healthcare industry
- Strategic partnership with Society of Teachers of Family Medicine
- Pending sale of Financial Services segment thereby moving it to discontinued operations.
- Synergies of the recent Walden acquisition
- Re-accreditation for American University of the Caribbean School of Medicine
Headwinds
- Impact of COVID-related headwinds associated with the Omicron variant that has further burdened healthcare professionals, which continues to negatively impact enrollments
- Decrease in new student enrollment was primarily attributable to COVID-related headwinds in Chamberlain’s post-licensure programs.
- Segment operating loss was $2.4 million, driven primarily by intangible amortization expense for Walden.
- Second quarter segment revenue decreased 2.0% to $139.1 million compared with the prior year for Chamberlain
- Diluted earnings per share was $0.36 compared with diluted earnings per share of $0.44 in the prior year
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.7%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+0.7%
Avg return
30 days after
43%
29 / 67 earnings
Positive
+22.8%
Q1 2013
Best reaction
-33.2%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +13.2% | +10.2% | +8.0% | |
| Q2 2026 | -7.8% | -14.2% | -15.5% | |
| Q1 2026 | -33.2% | -31.2% | -34.7% | |
| Q3 2025 | +16.4% | +11.9% | +10.7% | |
| Q2 2025 | +4.6% | +7.5% | -0.1% | |
| Q1 2025 | +12.0% | +8.7% | +23.8% | |
| Q4 2024 | -7.3% | -2.1% | -2.2% | |
| Q3 2024 | +18.9% | +24.8% | +27.5% | |
| Q2 2024 | -13.9% | -17.5% | -15.6% | |
| Q1 2024 | +12.5% | +16.6% | +29.4% | |
| Q4 2023 | -1.1% | -4.0% | -0.8% | |
| Q3 2023 | +4.5% | +2.0% | +2.4% | |
| Q2 2023 | +13.7% | +3.1% | +2.2% | |
| Q1 2023 | +2.4% | +6.9% | -2.1% | |
| Q4 2022 | -3.1% | -2.6% | -2.8% | |
| Q3 2022 | +6.4% | +10.9% | +17.5% | |
| Q2 2022 | -12.7% | -16.0% | -15.2% | |
| Q1 2022 | -12.9% | -6.0% | -16.6% | |
| Q4 2021 | +1.3% | +0.3% | +11.8% | |
| Q3 2021 | -6.9% | -8.3% | -1.3% | |
| Q2 2021 | +0.1% | +0.9% | -2.8% | |
| Q1 2021 | +3.7% | +11.0% | +16.6% | |
| Q4 2020 | -4.4% | -6.5% | -25.9% | |
| Q3 2020 | +3.7% | +9.8% | +11.5% | |
| Q2 2020 | +3.1% | -3.0% | -14.9% | |
| Q1 2020 | -19.2% | -16.8% | -7.8% | |
| Q4 2019 | -12.5% | -14.6% | -20.9% | |
| Q3 2019 | -7.6% | -9.0% | -11.4% | |
| Q2 2019 | -3.3% | -3.6% | -4.1% | |
| Q1 2019 | +4.3% | +10.7% | +14.0% | |
| Q4 2018 | -15.8% | -13.5% | -20.0% | |
| Q3 2018 | -5.7% | -3.0% | +1.4% | |
| Q2 2018 | +7.1% | +3.7% | +12.3% | |
| Q1 2018 | -2.7% | +1.1% | +9.7% | |
| Q4 2017 | +4.3% | +4.0% | +8.1% | |
| Q3 2017 | -0.8% | +5.0% | +0.5% | |
| Q2 2017 | -0.5% | -3.0% | +0.2% | |
| Q1 2017 | +1.8% | +1.5% | +31.5% | |
| Q4 2016 | +17.7% | +11.8% | +4.3% | |
| Q3 2016 | +17.3% | — | — | |
| Q2 2016 | -14.2% | — | — | |
| Q1 2016 | -2.3% | — | — | |
| Q4 2015 | -7.7% | — | — | |
| Q3 2015 | -15.9% | — | — | |
| Q2 2015 | -17.9% | — | — | |
| Q1 2015 | +0.8% | — | — | |
| Q4 2014 | -3.2% | — | — | |
| Q3 2014 | +13.0% | — | — | |
| Q2 2014 | -2.6% | — | — | |
| Q1 2014 | +6.2% | — | — | |
| Q4 2013 | -9.5% | — | — | |
| Q3 2013 | -17.6% | — | — | |
| Q2 2013 | +19.1% | — | — | |
| Q1 2013 | +22.8% | — | — | |
| Q4 2009 | -2.2% | — | — | |
| Q4 2012 | -2.3% | — | — | |
| Q3 2012 | -0.4% | — | — | |
| Q2 2012 | -8.5% | — | — | |
| Q1 2012 | -0.8% | — | — | |
| Q4 2011 | +4.7% | — | — | |
| Q3 2011 | -1.4% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2010 | -1.1% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q1 2011 | -1.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro